Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.

Bone Marrow Transplantation
K Maas-BauerRobert Zeiser

Abstract

Glucocorticoid-refractory (SR) chronic (c) graft-versus-host disease (GVHD) is a multisystem immunological disease and the leading cause of non-relapse mortality (NRM) in patients surviving longer than 2 years after allogeneic hematopoietic cell transplantation. Both ruxolitinib (RUX) and extracorporeal photopheresis (ECP) have shown activity for SR-cGVHD which motivated us to treat refractory cGHVD patients with the RUX-ECP combination. In this retrospective survey, 23 patients received RUX-ECP as salvage therapy for SR-cGVHD. The best response (CR or PR) at any time point during treatment was 74% (17/23) including 9% (2/23) CR and 65% (15/23) PR. The 24-months-survival was 75% (CI 56.0-94.1). Newly diagnosed cytopenia occurred in 22% (5/23) and CMV reactivation was observed in 26% (6/23) of the patients. Serum levels of soluble interleukin-2 receptor (sIL-2R) correlated with response. Our retrospective analysis shows that the RUX-ECP combination is safe and has activity in a fraction of patients with SR-cGVHD, which needs validation in a prospective trial.

References

Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·S E NicholsonJ E Layton
Mar 23, 2006·Blood·Corey CutlerEdwin Alyea
Mar 2, 2012·The New England Journal of Medicine·Srdan VerstovsekHagop M Kantarjian
Oct 23, 2012·Bone Marrow Transplantation·A ClavertM Mohty
Apr 9, 2014·Blood·Silvia SpoerlNikolas von Bubnoff
Oct 29, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael BoyiadzisSteven Z Pavletic
Dec 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Madan H JagasiaMary E D Flowers
Jan 7, 2016·The New England Journal of Medicine·Nicolaus KrögerFrancesca Bonifazi
Dec 28, 2017·The New England Journal of Medicine·Robert Zeiser, Bruce R Blazar
Apr 23, 2020·The New England Journal of Medicine·Robert ZeiserUNKNOWN REACH2 Trial Group

❮ Previous
Next ❯

Software Mentioned

GraphPad
GraphPad Prism
SAS

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.